# Paulex Bio Announces Registration of Phase 1/2a Trial of PAL-119, an Oral Small Molecule Designed to Regenerate and Restore the Function of Insulin-Producing Beta Cells

- Source: PR Newswire M&A
- Published: 2026-11-02T12:33:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/paulex-bio-announces-registration-of-phase-12a-trial-of-pal-119-an-oral-small-molecule-designed-to-regenerate-and-restore-the-function-of-insulin-producing-beta-cells-302925540.html
- Canonical: https://groundlevelnews.com/story/paulex-bio-announces-registration-of-phase-1-2a-trial-of-pal-119-an-or-c5158d/

First-in-human study plans to enroll healthy volunteers and adults with Type 1 or Type 2 diabetes to evaluate PAL-119's safety and tolerability and explore its effects on the body's own insulin production SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Paulex Bio Inc., a biopharmaceutical company...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._